title: Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient.
abstract: OBJECTIVE
  The purpose of this paper was to review the literature concerning the treatment of chronic kidney disease-mineral bone disorder (CKD-MBD) in the elderly peritoneal dialysis (PD) patient.
  
  
  RESULTS
  Chronic kidney disease-mineral bone disorder is a major problem in the elderly PD patient, with its associated increased fracture risk, vascular calcification, and accelerated mortality fracture risk. Peritoneal dialysis, however, bears a lower risk than hemodialysis (HD). The approach to CKD-MBD prophylaxis and treatment in the elderly PD patient is similar to other CKD patients, with some important differences. Avoidance of hypercalcemia, hyperphosphatemia, and hyperparathyroidism is important, as in other CKD groups, and is generally easier to attain. Calcium-free phosphate binders are recommended for normocalcemic and hypercalcemic patients. Normalization of vitamin D levels to > 75 nmol/L (> 30 pg/L) and low-dose active vitamin D therapy is recommended for all patients. Hyperparathryoidism is to be avoided by using active vitamin D and cinacalcet. Particular attention should be paid to treating protein malnutrition. Fracture prophylaxis (exercise, use of walkers, dwelling modifications) are important. Hypomagnesemia is common in PD and can be treated with magnesium supplements. Vitamin K deficiency is also common and has been identified as a cause of vascular calcification. Accordingly, warfarin treatment for this age group is problematic.
  
  
  CONCLUSIONS
  While treatment principles are similar to other dialysis patient groups, physicians should be aware of the special problems of the elderly group.
authors.affiliation: Department of Medicine, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark heaf@dadlnet.dk.
authors.forename: James Goya
authors.initials: JG
authors.lastname: Heaf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018488:Bone Demineralization, Pathologic / Q000209:etiology / Q000517:prevention & control; D015519:Bone Density / Q000502:physiology*; D001851:Bone Diseases, Metabolic / Q000209:etiology* / Q000517:prevention & control*; D002118:Calcium / Q000627:therapeutic use; D019587:Dietary Supplements; D015444:Exercise / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D015577:Geriatric Assessment / Q000379:methods; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D008297:Male; D010530:Peritoneal Dialysis / Q000009:adverse effects* / Q000379:methods; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D018570:Risk Assessment; D016896:Treatment Outcome; D014807:Vitamin D / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use
chemical_list: D014812:Vitamin K; D014807:Vitamin D; D008274:Magnesium; D002118:Calcium
keywords: Peritoneal dialysis; geriatrics; mineral bone disease; parathyroid hormone; phosphate; vitamin D; warfarin